Just 4 years ago, one of us (MJK) co-chaired the Familial Hypercholesterolemia (FH) Foundation’s first FH Global Summit: Awareness to Action held in Annapolis, Maryland. The Summit brought together people from academia, government, the private sector, clinicians, as well as patients with the ambitious goals of raising awareness of FH, identifying key knowledge gaps, and Read More >Posted on by
In September 2016, the Cancer Moonshot Blue Ribbon Panel delivered a report with 10 ambitious recommendations to shape cancer research for the next five years. One recommendation is to “expand use of proven prevention and early detection strategies.” [PDF 199 KB] There is a lot we can do to prevent cancer now— even with no Read More >Posted on by
In a recent post, I reviewed the progress of genomics in public health over the past two decades and pondered on the lingering skepticism about genomics in the public health community. I propose that this skepticism is driven, at least in part, by 5 common misconceptions about the role of genomics in public health. In Read More >Posted on by
In 1996, a working group from the Centers for Disease Control and Prevention published an article in the American Journal of Public Health entitled: “From Genes to Public Health: Applications of Genetic Technology in Disease Prevention.” The agency-wide group assessed the implications of the Human Genome Project and related technologies for public health and disease Read More >Posted on by
On June 6-7, 2016, I had the honor of participating in the “Precision Public Health” summit hosted by the Gates Foundation and the White House Office of Science and Technology at the University of California in San Francisco. The summit focused on developing a global “precision” agenda to improve health and prevent death and disease Read More >Posted on by
The Shift From Personalized Medicine to Precision Medicine and Precision Public Health: Words Matter!
Advances in genomics and other ‘omic’ technologies have ushered in a new era variably called “personalized” or “precision” medicine, which takes into account individual genetic and other sources of variability in disease treatment and prevention. In the past decade, we have seen a significant growth in interest and usage of the terms personalized and precision Read More >Posted on by
Does genetic risk information improve healthy behavior? Let’s not throw out the baby with the bath water!
In a recent systematic review with meta-analysis, Hollands et al evaluated the impact of communicating genetic risk information on risk-reducing health behaviors and motivations for behavior change. The authors reviewed 18 studies with 7 behavioral outcomes, including smoking cessation, diet and physical activity. They found no significant effects of communicating DNA based risk estimates on Read More >Posted on by
We have previously blogged about the value (or lack thereof) of direct-to-consumer (DTC) genetic tests in improving health. In a 2011 blog entitled “think before you spit” we cautioned that there was very little evidence that the use of such tests improves health and prevents disease for healthy people in the population. The blog was Read More >Posted on by
Rare Disease Day is celebrated on the last day of February each year. On that day, millions of patients and their families around the world share their stories in order to raise awareness about rare diseases and their impact. There are thousands of diseases that are individually rare but collectively common. In the United States, Read More >Posted on by
We explore briefly the expanding role of population sciences in the implementation of the NIH Precision Medicine Initiative (PMI). The initiative includes a major component on cancer precision treatment, and a large scale cohort study program to generate knowledge applicable to all areas of health and disease, including cancer risk factors and outcomes. Genomics is Read More >Posted on by
- Content source: